RE: CLN's15 Jan 2024 07:52
“…. Michael Schmainda is converting a total of £18,500 convertible loan notes and associated interest, issued in March 2019, at a price of 2 pence, into 1,193,681 Ordinary Shares which will be issued to his wife, Kathleen Schmainda ’
KS is the brains behind the FDA’s and clinical trials. Do you think Mike has given her those to sell?
Likewise TB could have sold some of his stock by now but has accumulated.
23.28% + 5.38 is 28.66% that’l do!
He also knows how difficult the liquidity is here so any selling would have had to have been gradual. Well in reality it would be impossible as significant selling would trash the sp…. Hence….
I think TB is in it for a deal!
Still under 200m shares that’s an outstanding achievement!
With no CLN’s outstanding and no debt, revs from LA hospitals, NIH grants, royalty income known but not quantified has meant that we haven’t needed to raise cash for 2 years and assurances of more grant funding and or a JV the next news. It should be pretty interesting esp from a 7m mcap lol!
That news any combo of…
sell assets IB and or other tech to raise for contribution to clinical trials
Milestone deal on phase 2
JV on phase 2
Cash from vouchers
Children’s cancer funding
Other charity funding
Sell the lot!
Raise cash and go alone very unlikely if not impossible!
Main thing is we are pretty much self funded until the next steps are revealed. All of which imo point to a significantly higher sp!
Usual caveats
Trek
Sign In
Follow the stocks
